Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial.

Auteurs

Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, Guiot T, de Vries EGE, Schröder CP, Menke-van der Houven van Oordt CW, Maetens M, Majjaj S, Larsimont D, Rothé F, Sotiriou C, Gebhart G

  • Date de publication

    Oktober 2024

  • Type

    Article

  • Tijdschrift

    Clin Cancer Res

  • Naam van de onderzoeker

    LARSIMONT DENIS

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Anatomie Pathologique

  • PMID

    39470686

  • DOI

    10.1158/1078-0432.CCR-24-1007